2025-2031全球与中国RNase清除剂市场竞争策略及投资可行性研究报告 【全新修订】：2025年4月 【出版机构】：中智信投研究网 【内容部分有删减·详细可参中智信投研究网出版完整信息！】 【免费售后 服务一年，具体内容及订购流程欢迎咨询客服人员 】 报告目录 1 RNase清除剂市场概述 1.1 产品定义及统计范围 1.2 按照不同产品类型，RNase清除剂主要可以分为如下几个类别 1.2.1 全球不同产品类型RNase清除剂销售额增长趋势2020 VS 2024 VS 2031 1.2.2 液相RNase清除剂 4.6 全球主要厂商RNase清除剂产品类型及应用 1.2.3 固相RNase清除剂 1.3 从不同应用，RNase清除剂主要包括如下几个方面 1.3.1 全球不同应用RNase清除剂销售额增长趋势2020 VS 2024 VS 2031 2.1.1 全球RNase清除剂产能、产量、产能利用率及发展趋势（2020-2031） 2.1.2 全球RNase清除剂产量、需求量及发展趋势（2020-2031） 1.3.2 医疗 1.3.3 科研 1.4 RNase清除剂行业背景、发展历史、现状及趋势 ...

Core Viewpoint - The implementation plan for high-quality development in Changping District emphasizes its role as a hub for technological innovation and industrial upgrading, showcasing a modern innovative city with significant economic growth and development momentum [2][3]. Group 1: Economic Growth - Changping's GDP is projected to grow by 6.6% in 2024, making it the fastest-growing area in Beijing [3]. - Fixed asset investment in Changping is expected to increase by 16.4%, reaching a historical high [3]. - Per capita disposable income for residents is anticipated to rise by 5.6%, the highest growth rate in the city [3]. Group 2: Technological Innovation - Changping is home to 41 universities, 69 national and provincial key laboratories, and over 210 engineering technology centers, with more than one-third of the city's key laboratories located here [3][4]. - The research intensity in Changping maintains a high level at 6.5% [3]. - The National Energy Group's Beijing Low Carbon Clean Energy Research Institute has developed a new high-performance iron-based Fischer-Tropsch synthesis catalyst, generating over 5 billion yuan in economic benefits [5]. Group 3: Industrial Development - The advanced energy industry in Changping generates over 240 billion yuan, while the pharmaceutical and health industry has surpassed 100 billion yuan [6]. - Changping has established a "3+2" high-end industrial structure, focusing on advanced energy, pharmaceutical health, and advanced manufacturing, along with rapid development in technology services and innovation finance [6][8]. - The advanced manufacturing sector in Changping is integrating smart, automated, and precision manufacturing technologies [7]. Group 4: Urban Renewal - Changping is undergoing significant urban renewal, transforming old factories and communities into research parks and cultural centers [9][10]. - The area is implementing a "science + city" concept, enhancing the integration of production, living, and ecological spaces to create a livable and workable "future city" [10][11]. - The district has seen an annual growth of over 30% in municipal investment, with a total rail transit mileage exceeding 130 kilometers, ranking first among Beijing's plain new cities [11].

| 名称 持有数量(万股) | | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 深圳华大基因（300676）科技有限公司 | 14128.56 | 34.16 | -748.83 | | 深圳生华投资企业(有限合伙) | 3447.05 | 8.34 | 不变 | | 中国银行股份有限公司-华宝中证医疗交易型开放式指数 | | | | | 证券投资基金 | 814.89 | 1.97 | -21.65 | | 中国工商银行股份有限公司-易方达创业板交易型开放式 | 596.35 | 1.44 | -47.26 | | 指数证券投资基金 | | | | | 香港中央结算有限公司 | 521.97 | 1.26 | 213.00 | | 交通银行股份有限公司-万家行业优选混合型证券投资基 金(LOF) | 500.01 | 1.21 | -100.00 | | 深圳华大三生园科技有限公司 | 393.58 | 0.95 | 不变 | | 法国巴黎银行-自有资金 | 353.04 | 0.85 | 新进 | | 深圳华大基因股份有限公 ...

領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 內幕消息 業務更新 本公告乃由領航醫藥及生物科技有限公司（「本公司」，連同其附屬公司統稱「本 集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)條 以及香港法例第571章證券及期貨條例第XIVA部之內幕消息條文（定義見上市 規則）而作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 此計劃符合全球數碼轉型趨勢，並提供機會令本集團的收益來源更多元化，同 時提升在新興行業的競爭地位。 資金及管理 為支持該計劃，本公司可能透過不同方式籌集資金，包括配售，以及向股東或 財務機構借貸。本公司亦可能擴大董事會及高級管理層團隊以納入合資格人 士以確保新項目的成功。 前景及管理層觀點 本公司董事（「董事」）會（「董事會」）欣然提供本集團業務計劃的最 ...

Group 1 - Berry Genomics (000710.SZ) released its 2024 annual report on April 25, 2025, indicating that as of April 24, 2025, 44 institutional investors disclosed holding A-shares, totaling 79.7934 million shares, which accounts for 22.57% of the total share capital [1] - The top ten institutional investors include Chengdu Tianxing Instrument (Group) Co., Ltd., Hongling Siqi (Zhuhai) M&A Equity Investment Enterprise (Limited Partnership), and others, with a combined holding ratio of 22.43%, reflecting a decrease of 1.55 percentage points compared to the previous quarter [1] - In the public fund sector, 37 new public funds were disclosed this period compared to the previous quarter, including funds such as Huatai-PB CSI Precision Medicine Index (LOF) A and Medical Device ETF [1] Group 2 - Foreign institutional investors that did not disclose holdings this period include MORGAN STANLEY & CO. INTERNATIONAL PLC, BARCLAYS BANK PLC, and J.P. Morgan Securities PLC - proprietary funds [2]

Core Viewpoint - The company focuses on food safety rapid testing and animal diagnostics, aiming to expand its market presence both domestically and internationally through innovative products and strategic partnerships [5][10][19]. Company Overview - The company specializes in food safety rapid testing and is expanding into animal diagnostics, providing comprehensive testing solutions across various stages of the food supply chain [5][10]. - The main products include rapid test reagents, testing instruments, and related services, ensuring food safety from production to retail [6][8]. Business Segments Food Safety Rapid Testing - The company offers a range of rapid test products, including immunochromatographic test strips and ELISA kits, applicable to various food categories such as dairy, meat, and vegetables [6][7]. - The company has developed a high-throughput multi-residue testing card for pesticide residues, capable of detecting 16 types of pesticides simultaneously within 9 minutes [8][22]. Animal Diagnostics - The animal diagnostics segment is managed by a wholly-owned subsidiary, focusing on rapid testing for livestock and companion animals, including pregnancy tests and pathogen detection [10][24]. - The company aims to leverage its existing customer base in food safety to enhance sales in animal diagnostics, particularly in markets with significant livestock populations [24]. Market Strategy - The company is deepening its international strategy, targeting untapped markets in dairy product testing and other areas, with a focus on obtaining local certifications and building partnerships [19][20]. - The global market for mycotoxin testing kits is projected to reach $825.7 million by 2028, indicating significant growth potential for the company's products in this area [19]. Regulatory Environment - Increasing domestic regulations on food safety are driving demand for testing services, as companies seek to comply with stricter standards [25]. - The company is positioned to benefit from heightened consumer awareness regarding food safety, leading to increased testing requirements from food producers and retailers [25]. Technological Innovation - The company has developed an automated digital testing platform that enhances testing efficiency and reduces costs for clients, integrating data management and real-time monitoring [26]. - A new chemiluminescence technology platform allows for multi-parameter testing in a single device, streamlining the testing process and improving accuracy [27]. Financial Performance - The company has maintained a stable financial position, with no need for restating previous financial data, indicating consistent operational performance [30]. - The company has received various certifications, reflecting its commitment to quality and innovation in the testing industry [29].

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -1.4140 | -0.7500 | -88.53 | 1.7220 | | 每股净资产（元） | 13.03 | 14.82 | -12.08 | 19.04 | | 每股公积金(元) | 12.39 | 12.4 | -0.08 | 14.9 | | 每股未分配利润(元) | -0.15 | 1.25 | -112 | 2.93 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.26 | 1.71 | -26.32 | 5.22 | | 净利润(亿元) | -1.57 | -0.84 | -86.9 | 1.59 | | 净资产收益率(%) | -10.05 | -4.93 | -103.85 | 19.82 | 三、分红送配方案情况 不分配不转增 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 1356.09万股，累计占 ...

金十数据4月24日讯，睿昂基因发布一季报，营业收入为5473.80万元，同比下降14.72%；归属于上市公 司股东的净利润为335.50万元，同比增长529.26%。净利润增长主要系子公司长春技特收到流式细胞相 关研究项目政府补助尾款180万；收回前期单项计提的一笔应收坏账247.63万元。 睿昂基因：一季度净利润同比增长529.26% ...

Core Viewpoint - The major industry ETFs in the US stock market showed mixed performance, with semiconductor and internet stock index ETFs leading the gains [1]. Group 1: Semiconductor and Internet Stocks - The semiconductor ETF (SMH) increased by 4.56 to 203.47, representing a rise of 2.29% with a trading volume of 678,200 shares and a total value of 24.05 billion [1]. - The internet stock index ETF (FDN) rose by 3.47 to 222.01, marking a gain of 1.59% with a trading volume of 8,124 shares and a total value of 147.41 billion [1]. Group 2: Other Technology and Sector ETFs - The technology sector ETF (XLK) saw an increase of 2.88 to 200.92, which is a 1.45% rise with a trading volume of 312,500 shares and a total value of 639.04 billion [1]. - The gold ETF (GLD) rose by 2.21 to 305.87, reflecting a 0.73% increase with a trading volume of 1,639,300 shares and a total value of 827.36 billion [1]. - The energy sector ETF (XLE) increased by 0.53 to 81.77, a rise of 0.65% with a trading volume of 776,800 shares and a total value of 204.77 billion [1]. Group 3: Underperforming ETFs - The biotechnology index ETF (IBB) decreased by 0.17 to 121.83, a decline of 0.14% with a trading volume of 67,616 shares and a total value of 96.73 billion [1]. - The regional bank ETF (KRE) fell by 0.10 to 53.45, representing a decrease of 0.18% with a trading volume of 1,204,100 shares and a total value of 44.61 billion [1]. - The financial sector ETF (XLF) declined by 0.15 to 47.56, a drop of 0.32% with a trading volume of 2,697,600 shares and a total value of 529.42 billion [1].

Core Insights - Berry Genomics (000710) reported a revenue of 1.078 billion yuan for 2024, representing a year-on-year decline of 6.36% [1] - The net loss attributable to shareholders was 192 million yuan, compared to a net loss of 427 million yuan in the same period last year [1] - The basic earnings per share were -0.5443 yuan per share [1] - The company announced plans not to distribute cash dividends, issue bonus shares, or increase capital through reserves [1]